No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
304 |
4. Check minimum number of eventsNone |
304 |
5. Include endpointsNone |
304 |
6. Filter based on genotype QC (FinnGen only) |
267 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified primary disorders of muscles
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1716 | 804 | 901 |
| Only index persons | 1507 | 719 | 788 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 51.52 | 52.43 | 50.70 |
| Only index persons | 51.61 | 52.14 | 51.12 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 267 | 139 | 128 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.06 |
| Median age at first event (years) | 53.08 | 53.82 | 52.28 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 277
- Matched controls
- 2770
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
+∞
241.4
195
*
G71.8
ICD-10 Finland
Other primary disorders of muscles
+∞
118.5
105
*
G72.9
ICD-10 Finland
Myopathy, unspecified
1320.7
98.3
90
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
74.4
68
*
R1250
NOMESCO Finland
Evaluation of functional capability
16.0
51.5
47
35
Z31.5
ICD-10 Finland
Genetic counselling
8.6
47.0
70
105
G71.18
ICD-10 Finland
Other myotonic disease
+∞
37.3
35
*
NXL00
NOMESCO Finland
Biopsy of muscle
407.7
36.9
36
*
SPAT1229
SPAT
Assessment of need for aid
8.7
34.7
48
65
L28
ICPC
Limited function/disability (L)
4.9
33.9
100
284
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.7
33.7
62
115
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
377.1
33.7
33
*
N03AE01
ATC
clonazepam; systemic
7.2
29.9
49
80
G72.8
ICD-10 Finland
Other specified myopathies
167.5
29.3
30
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.0
28.4
48
81
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
64.4
25.5
29
5
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.6
24.2
70
191
G71.00
ICD-10 Finland
Muscular dystrophy benign [Becker]
+∞
23.2
22
*
J96.1
ICD-10 Finland
Chronic respiratory failure
21.1
21.9
32
17
R13
ICD-10 Finland
Dysphagia
5.6
20.4
42
85
G71.11
ICD-10 Finland
Dystrophia myotonica [Steinert]
+∞
20.0
19
*
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
+∞
20.0
19
*
R4120
NOMESCO Finland
Occupational therapy
5.1
19.5
45
101
A28
ICPC
Limited function/disability NOS
3.6
18.0
75
261
Z3226
NOMESCO Finland
Physiotherapist
3.3
16.9
84
326
G71.0
ICD-10 Finland
Muscular dystrophy
+∞
16.8
16
*
M60.8
ICD-10 Finland
Other myositis
180.4
16.7
17
*
XF404
NOMESCO Finland
Ambulatory ECG
4.4
16.4
45
116
R5110, ,
SPAT
4.4
16.1
44
113
N99
ICPC
Neurological disease other
20.7
15.8
23
12
G71.12
ICD-10 Finland
Myotonia congenita
+∞
15.8
15
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
169.2
15.6
16
*
M60.9
ICD-10 Finland
Myositis, unspecified
47.9
15.3
18
*
R52.2
ICD-10 Finland
Other chronic pain
6.1
14.9
27
48
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
11.8
14.9
27
25
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
4.1
14.8
45
125
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.1
14.2
73
286
N28
ICPC
Limited function/disability (N)
18.8
14.1
21
12
L99
ICPC
Musculoskeletal disease other
12.4
13.6
24
21
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
73.3
12.7
14
*
M33.2
ICD-10 Finland
Polymyositis
73.3
12.7
14
*
L19
ICPC
Muscle symptom/complaint NOS
6.6
12.7
21
34
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.4
12.4
50
168
Z50.1
ICD-10 Finland
Other physical therapy
4.8
12.0
28
63
N03AX16
ATC
[U] pregabalin
2.7
11.9
83
380
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.7
11.9
87
408
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.0
11.8
59
226
G71.06
ICD-10 Finland
Muscular dystrophy severe [Duchenne]
+∞
11.5
11
*
R4130
NOMESCO Finland
Speech therapy
5.9
11.4
21
38
R4110
NOMESCO Finland
Physiotherapy
2.5
11.3
102
527
N18
ICPC
Paralysis/weakness
11.9
11.2
20
18
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
16.4
11.0
17
11
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
4.0
10.9
33
91
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
3.9
10.7
33
92
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
10.7
84
405
R4190
NOMESCO Finland
Nutritional therapy
4.1
10.5
30
79
G71.28
ICD-10 Finland
Other congenital myopathy
+∞
10.5
10
*
G71.25
ICD-10 Finland
Congenital muscular dystrophy NOS
+∞
10.5
10
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.4
10.5
93
474
N29
ICPC
Neurological sympt/complt other
11.2
10.4
19
18
C10AX09
ATC
ezetimibe; oral
2.7
10.4
64
273
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.0
9.8
47
175
N07AA02
ATC
pyridostigmine; systemic
103.4
9.5
10
*
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
9.4
9
*
33030
ICD-8 Finland
Hereditary neuromuscular disorders, Progressive muscular dystrophy
+∞
9.4
9
*
N03AX12
ATC
[U] gabapentin; oral
2.7
9.3
59
255
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.9
9.2
21
46
H02AB06
ATC
prednisolone; systemic
2.2
9.0
146
944
M03BX01
ATC
baclofen; systemic
9.1
8.9
18
21
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.4
8.9
23
56
G47.3
ICD-10 Finland
Sleep apnoea
2.3
8.9
82
421
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
7.0
8.8
21
32
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.1
8.7
25
66
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
9.5
8.7
17
19
N03AF01
ATC
carbamazepine; oral, rectal
4.1
8.6
24
62
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
8.6
90
487
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.9
8.5
45
176
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
5.1
8.5
18
37
M41.4
ICD-10 Finland
Neuromuscular scoliosis
92.8
8.5
9
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
15.1
8.3
13
9
ZYC01
NOMESCO Finland
Remote contact by phone
3.4
8.2
31
99
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
34.4
8.1
10
*
WZC00, ,
SPAT
2.6
8.1
51
219
N02AX02
ATC
tramadol; systemic, rectal
2.1
8.0
126
794
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.6
8.0
27
80
N06AX21
ATC
duloxetine; oral
2.7
7.9
47
196
XG466
NOMESCO Finland
Sleep oxymetry
6.7
7.9
19
30
RK110, ,
NOMESCO Finland
15.6
7.8
12
8
TJD20
NOMESCO Finland
Change of gastrostomy tube
19.0
7.7
11
6
Z3231
NOMESCO Finland
Registered nurse
2.1
7.6
95
548
R06.0
ICD-10 Finland
Dyspnoea
2.1
7.5
90
510
Z99.1
ICD-10 Finland
Dependence on respirator
82.2
7.5
8
*
N03AX09
ATC
lamotrigine; oral
3.7
7.4
24
69
Z3229
NOMESCO Finland
Other healthcare associate professional
2.9
7.4
36
134
ZX120
NOMESCO Finland
Intravenous
2.9
7.4
38
146
XF400
NOMESCO Finland
ECG with 12 standard connections
2.4
7.4
55
255
3591A
ICD-9 Finland
Muscular dystrophies and other myopathies, Hereditary progressive muscular dystrophy
+∞
7.3
7
*
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
7.3
7
*
SPAT1216
SPAT
Assessment of functional ability
2.6
7.3
47
203
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.6
7.3
25
75
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
4.7
7.3
17
38
R42
ICD-10 Finland
Dizziness and giddiness
2.2
7.1
72
382
R60.9
ICD-10 Finland
Oedema, unspecified
3.8
7.0
22
62
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.8
7.0
38
151
Z2446
NOMESCO Finland
Social worker
2.8
7.0
36
139
R03BA08
ATC
ciclesonide; inhalant
3.0
6.8
32
117
RD210, ,
NOMESCO Finland
6.2
6.7
17
29
SPAT1153
SPAT
Removal of sutures
2.0
6.7
89
521
RF410, ,
NOMESCO Finland
12.7
6.6
11
9
ZXE10
NOMESCO Finland
More than one and less than three hours
2.0
6.6
108
680
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.7
6.5
36
144
TAB00
NOMESCO Finland
Lumbar puncture
3.4
6.4
23
71
K59.09
ICD-10 Finland
Constipation, unspecified
3.2
6.4
26
87
N02BF01
ATC
gabapentin; oral
2.6
6.4
40
170
XA402
NOMESCO Finland
ENMG
5.8
6.4
17
31
Z09.0
ICD-10 Finland
Follow-up examination after surgery for other conditions
3.3
6.3
24
77
I42.0
ICD-10 Finland
Dilated cardiomyopathy
7.3
6.3
14
20
SPAT1231
SPAT
Assessment of adjustments needed in living environment
7.3
6.3
14
20
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
6.3
6
*
Z93.1
ICD-10 Finland
Gastrostomy status
+∞
6.3
6
*
3599X
ICD-9 Finland
Muscular dystrophies and other myopathies, Myopathy, unspecified
+∞
6.3
6
*
N02BF02
ATC
pregabalin; oral
3.0
6.1
27
95
H02AB09
ATC
hydrocortisone; systemic
5.4
6.1
17
33
RF420, ,
NOMESCO Finland
8.9
6.1
12
14
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.1
6.1
26
90
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
50
14
43.36
81.40
1.5
1.6
7.48
8.24
u/l
0.09
43
14
196
710
7.02
54.12
4.4
2.1
889.87
178.89
u/l
1.95
190
672
43
75
6.60
24.50
1.7
1.3
—
—
—
0
0
137
631
3.32
21.43
4.2
3.6
1220.01
1185.94
ng/l
0.02
127
526
192
1190
3.00
16.12
9.0
8.6
1.21
1.21
mmol/l
0.11
175
1037
26
19
14.97
15.86
1.3
1.1
—
—
—
0
0
178
1085
2.79
14.97
9.2
7.9
1.21
1.21
mmol/l
0.59
170
1007
26
26
10.91
13.80
1.3
1.2
—
79.00
—
0
6
167
1036
2.54
12.75
5.9
5.7
36.25
36.31
g/l
0.05
162
981
67
272
2.93
12.06
6.6
5.7
6.15
5.80
kpa
1.92
67
265
65
265
2.90
11.58
6.7
5.7
2.18
1.71
mmol/l
0.60
57
231
167
1071
2.41
11.35
4.0
2.7
78.23
76.48
nmol/l
0.34
158
974
143
863
2.36
11.10
4.6
3.3
—
—
—
0
0
44
154
3.21
10.15
3.3
3.6
134.47
196.64
ng/l
0.50
38
140
73
338
2.57
10.04
8.2
8.0
104.19
104.54
mmol/l
0.29
73
338
197
1420
2.34
9.39
7.6
5.8
6.27
6.57
mmol/l
1.58
189
1346
180
1256
2.24
9.19
5.1
3.6
0.00
0.00
estimate
-0.00
38
260
181
1274
2.21
8.93
5.2
3.7
0.00
0.00
estimate
-0.00
37
239
55
235
2.67
8.82
5.6
5.4
4.61
4.57
kpa
0.06
55
230
179
1272
2.15
8.38
5.2
3.7
0.00
6.25
estimate
0.50
37
260
115
699
2.10
8.10
4.0
3.2
0.53
0.37
e6/l
0.27
90
506
58
271
2.44
7.67
8.1
10.7
1.17
1.11
mmol/l
0.03
48
237
142
948
2.02
7.61
5.2
3.5
0.00
0.01
estimate
0.50
34
211
229
1830
2.45
7.58
12.1
8.3
79.96
82.92
u/l
0.49
224
1735
25
78
3.42
6.88
3.2
2.5
25.55
24.67
mmol/l
0.46
25
78
175
1288
1.97
6.78
8.0
7.1
12.42
12.51
umol/l
0.02
168
1223
75
414
2.11
6.60
3.1
2.5
14.32
13.73
umol/l
0.28
70
391
72
392
2.13
6.57
2.1
2.1
—
—
—
0
0
81
462
2.06
6.53
5.0
3.9
92.51
266.74
ng/l
1.45
71
344
46
208
2.45
6.49
5.7
4.6
5.35
5.10
kpa
1.19
46
202
42
183
2.53
6.40
5.6
4.9
1.69
1.22
mmol/l
0.31
37
139
122
808
1.91
6.37
3.7
3.5
2.37
2.36
mmol/l
0.54
113
744
42
188
2.45
6.04
2.4
2.7
71.38
66.23
ml/min/173m2
0.22
13
83
27
96
3.01
6.03
1.3
1.3
0.20
4.42
u/ml
—
5
6
71
397
2.06
5.99
3.1
3.2
2.33
1.92
e6/l
0.18
40
193
76
437
2.02
5.93
3.3
3.0
0.84
0.78
e6/l
0.05
46
231
138
973
1.83
5.75
2.2
2.0
95.43
97.29
pmol/l
0.17
73
490
110
737
1.82
5.31
3.0
2.7
55.06
62.35
u/l
0.59
103
687
185
1449
1.83
5.26
12.8
11.1
4.10
3.97
e9/l
0.33
166
1252
215
1771
1.96
5.15
6.8
4.6
12.00
10.55
mm/h
0.89
206
1639
48
244
2.17
5.14
8.6
11.0
122.58
121.85
g/l
0.09
48
239
54
288
2.09
5.11
1.9
2.0
—
—
—
0
0
10
12
8.60
5.10
4.8
3.9
93.70
145.69
ug/l
—
10
12
124
876
1.75
4.91
4.6
3.6
55.93
32.62
ng/l
0.98
103
601
27
108
2.66
4.88
2.1
2.4
5.42
5.48
iu/ml
0.01
11
28
84
531
1.84
4.83
2.1
2.1
2.20
1.35
mg/l
0.35
69
428
31
134
2.48
4.80
3.4
4.5
1.90
1.25
%
1.70
31
134
20
70
3.00
4.60
3.0
2.3
4.91
2.21
index
0.66
11
44
73
449
1.85
4.55
3.5
2.6
2.47
2.44
mmol/l
1.16
65
396
30
131
2.45
4.55
3.4
4.5
0.60
0.62
%
0.07
30
131
22
84
2.76
4.35
4.6
2.9
—
—
—
0
0
11
20
5.68
4.33
1.1
1.0
—
—
—
0
0
53
300
1.95
4.23
1.9
2.0
—
—
—
0
0
14
35
4.16
4.16
1.1
1.1
—
—
—
0
0
19
70
2.84
4.01
1.4
1.4
0.21
0.06
iu/ml
—
7
13
41
216
2.05
3.99
10.1
10.2
25.55
24.96
mmol/l
0.43
41
216
24
101
2.51
3.94
1.4
1.7
—
—
—
0
0
13
33
4.08
3.85
1.2
1.1
—
—
—
0
0
118
866
1.63
3.80
5.2
3.7
50.17
33.14
u/l
1.93
112
824
13
34
3.96
3.74
1.6
1.2
—
—
—
0
0
97
681
1.65
3.71
6.3
3.7
0.00
0.02
estimate
0.96
37
243
99
704
1.63
3.58
3.6
2.9
0.00
0.00
estimate
-0.00
35
205
8
13
6.30
3.52
1.4
1.0
—
—
—
0
0
82
560
1.66
3.46
6.0
3.7
1.02
1.02
kg/l
0.41
55
373
13
42
3.20
3.41
4.3
2.6
17.07
16.19
%
0.53
13
42
21
89
2.47
3.41
1.8
2.1
2.12
3.74
ug/l
0.21
21
81
9
18
5.13
3.40
1.4
1.1
—
—
—
0
0
61
386
1.74
3.39
2.9
2.6
30.22
29.40
s
0.66
61
381
57
354
1.77
3.38
2.0
1.6
1380.80
1217.96
nmol/l
0.43
44
270
11
28
4.05
3.32
1.7
1.3
—
—
—
0
0
214
1854
1.68
3.24
5.5
4.2
15.30
14.64
pmol/l
2.73
203
1694
11
29
3.91
3.22
1.5
1.2
—
—
—
0
0
243
2184
1.92
3.21
6.6
5.1
1.96
1.87
mu/l
0.68
235
2019
35
190
1.96
3.15
2.8
2.5
16.22
14.43
au/ml
—
5
14
11
30
3.77
3.12
1.7
1.2
—
—
—
0
0
11
30
3.77
3.12
1.7
1.2
—
—
—
0
0
10
25
4.11
3.11
1.3
1.8
—
—
—
0
0
10
25
4.11
3.11
1.3
1.8
—
—
—
0
0
10
25
4.11
3.11
1.3
1.8
—
—
—
0
0
35
191
1.95
3.10
1.4
1.4
338.79
363.09
u/ml
0.04
35
176
16
62
2.68
3.10
3.3
4.3
27.94
35.71
umol/l
1.27
16
56
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
57
2.72
3.01
3.4
3.2
0.35
0.36
iu/ml
—
6
31
87
624
1.57
2.95
3.1
2.4
3.07
2.94
mg/l
0.13
79
540
11
33
3.43
2.84
1.7
1.2
—
—
—
0
0
25
125
2.10
2.81
1.6
1.3
—
—
—
0
0
18
80
2.34
2.67
1.2
2.5
9.74
10.45
g/l
0.38
18
75
18
80
2.34
2.67
1.3
1.9
—
—
—
0
0
13
49
2.73
2.66
1.8
1.4
—
—
—
0
0
12
41
3.01
2.65
7.0
2.7
5.47
4.99
kpa
1.08
12
41
240
2179
1.76
2.64
22.8
14.2
95.75
83.99
ml/min/173m2
7.06
222
2005
7
15
4.76
2.61
1.0
1.0
—
—
—
0
0
32
180
1.88
2.61
1.7
1.2
226.52
189.10
u/ml
—
9
71
26
136
2.01
2.61
1.7
1.8
—
—
—
0
0
18
82
2.28
2.53
1.5
2.0
—
—
—
0
0
26
138
1.98
2.51
4.3
3.5
4.79
4.63
pmol/l
0.39
26
124
59
401
1.60
2.48
1.2
1.3
3.60
8.83
u/ml
1.14
33
157
16
70
2.36
2.46
1.3
2.7
0.00
0.00
g/l
-0.00
16
64
17
77
2.29
2.43
1.4
2.9
0.29
1.09
g/l
0.66
17
72
6
12
5.08
2.41
1.5
1.9
—
—
—
0
0
6
12
5.08
2.41
1.5
1.9
—
—
—
0
0
6
12
5.08
2.41
1.5
1.9
—
—
—
0
0
6
12
5.08
2.41
1.5
1.9
—
—
—
0
0
9
27
3.41
2.41
1.2
2.1
—
—
—
0
0
18
84
2.22
2.40
1.4
2.7
3.16
2.95
g/l
0.61
18
79
19
91
2.17
2.39
1.4
2.6
3.48
3.57
g/l
0.27
19
86
19
91
2.17
2.39
1.4
2.6
7.57
7.15
g/l
0.70
19
86
19
91
2.17
2.39
1.4
2.6
4.46
4.32
g/l
0.27
19
86
11
39
2.89
2.37
2.0
2.4
7.30
8.48
pmol/l
0.23
11
39
17
78
2.26
2.36
1.5
1.4
273.83
314.36
ug/g
0.33
12
45
255
2376
1.92
2.31
25.4
15.0
21.49
22.49
mg/l
0.23
232
1889
17
79
2.23
2.30
2.2
2.1
—
—
—
0
0
7
18
3.96
2.26
1.3
2.0
0.71
0.83
index
—
7
18
13
54
2.48
2.23
1.2
1.8
—
—
—
0
0
88
667
1.47
2.23
1.3
1.4
0.69
1.46
u/ml
1.29
14
180
10
35
2.93
2.23
1.7
1.9
—
—
—
0
0
8
24
3.40
2.19
2.6
3.7
—
—
—
0
0
237
2178
1.61
2.08
6.3
6.1
38.26
39.04
mmol/mol
0.65
226
2055
75
558
1.47
2.07
3.4
2.4
—
—
—
0
0
7
20
3.56
2.07
3.0
1.5
2.29
4.27
mg/l
—
7
20
62
444
1.51
2.06
1.4
1.3
16.38
32.49
iu/ml
1.81
15
149
6
15
4.06
2.05
1.0
1.0
—
—
—
0
0
78
591
1.45
1.95
2.7
3.2
335.35
340.18
umol/l
0.17
71
522
11
45
2.50
1.95
1.9
1.1
69.17
58.89
iu/ml
—
6
9
8
27
3.02
1.95
2.9
2.6
0.56
0.58
e9/l
—
8
27
6
16
3.81
1.94
1.0
1.1
—
—
—
0
0
137
1152
1.37
1.86
4.0
3.1
115.35
107.44
ug/l
0.17
131
1089
14
68
2.12
1.73
1.6
1.5
—
—
—
0
0
15
75
2.06
1.73
2.1
1.2
—
—
—
0
0
15
75
2.06
1.73
2.1
1.9
—
—
—
0
0
6
19
3.20
1.67
1.0
1.3
103.00
88.74
pmol/l
—
6
19
6
19
3.20
1.67
1.0
1.2
1.90
1.81
mmol/l
—
6
19
7
25
2.85
1.66
1.0
1.0
—
—
—
0
0
25
153
1.70
1.59
1.3
1.6
21.05
24.02
iu/l
0.17
17
122
18
100
1.86
1.57
1.7
1.7
12.28
8.51
u/l
0.36
12
69
8
33
2.47
1.55
1.1
1.5
—
—
—
0
0
11
51
2.20
1.52
3.3
5.8
—
3651.43
—
0
7
14
72
1.99
1.51
1.1
1.8
—
—
—
0
0
11
52
2.16
1.46
1.4
2.1
—
—
—
0
0
11
52
2.16
1.46
1.2
2.0
—
—
—
0
0
79
629
1.36
1.46
1.9
1.7
22.50
21.36
nmol/l
0.27
71
535
13
66
2.02
1.46
1.6
1.5
145.29
137.55
au/ml
—
7
23
5
16
3.16
1.44
1.2
2.1
—
—
—
0
0
35
240
1.52
1.44
12.9
7.8
—
—
—
0
0
14
74
1.94
1.41
1.6
1.5
—
—
—
0
0
5
17
2.98
1.36
1.2
3.0
—
—
—
0
0
5
17
2.98
1.36
1.2
3.0
—
—
—
0
0
9
42
2.18
1.35
1.2
2.1
—
—
—
0
0
125
1075
1.30
1.33
3.2
2.9
—
—
estimate
—
0
0
26
170
1.58
1.31
1.9
1.5
—
—
—
0
0
9
43
2.13
1.31
1.7
1.3
—
—
—
0
0
9
43
2.13
1.31
1.7
1.3
—
—
—
0
0
32
221
1.51
1.28
1.9
4.5
25.27
26.39
ug/l
0.01
23
174
9
44
2.08
1.28
1.4
1.1
—
—
—
0
0
43
316
1.43
1.27
7.3
4.2
5.80
8.06
umol/l
0.90
35
284
14
78
1.84
1.23
1.6
1.3
—
—
—
0
0
13
72
1.85
1.17
1.7
1.5
100.71
268.05
u/ml
—
7
37
18
278
0.62
1.13
1.6
2.0
4.02
3.54
ratio
0.47
12
218
34
249
1.42
1.04
3.7
2.6
39.18
29.22
u/l
0.77
28
204
5
22
2.30
1.04
2.4
4.1
512.40
681.14
mg
—
5
22
221
2078
1.31
1.04
27.8
19.3
13.86
13.52
%
2.63
221
2062
9
52
1.75
0.93
1.3
1.2
—
—
—
0
0
13
78
1.70
0.93
1.4
1.2
—
—
—
0
0
5
105
0.47
0.90
1.4
1.1
1.00
0.88
g/l
—
5
105
12
71
1.72
0.90
1.4
4.1
1.46
4.20
ratio
—
7
37
66
548
1.27
0.89
4.7
4.2
22.20
22.49
%
0.05
26
240
94
1074
0.81
0.89
2.2
1.9
1.45
1.38
mmol/l
0.30
82
915
81
690
1.25
0.88
4.8
4.8
1.71
1.74
ug/l
0.03
76
618
8
44
1.84
0.86
1.3
1.9
—
—
—
0
0
13
80
1.66
0.86
1.4
1.2
—
—
—
0
0
6
31
1.96
0.85
1.7
1.4
—
—
—
0
0
232
2214
1.29
0.83
5.2
4.8
5.80
5.89
mmol/l
0.46
218
2049
27
199
1.40
0.82
1.8
1.4
—
—
—
0
0
0
28
0.00
0.76
0.0
1.9
—
—
—
0
0
21
150
1.43
0.76
10.6
12.5
15.68
16.10
%
0.27
21
144
7
44
1.61
0.65
1.1
1.1
—
—
—
0
0
15
210
0.70
0.63
1.1
1.8
3.64
3.49
mmol/l
—
9
150
10
63
1.61
0.62
2.1
1.4
—
—
—
0
0
6
38
1.59
0.54
2.0
1.4
—
—
—
0
0
9
64
1.42
0.52
1.1
2.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
5
36
1.40
0.38
1.4
1.3
—
—
—
0
0
215
2086
1.14
0.36
32.2
20.1
331.59
333.03
g/l
1.26
215
2080
6
43
1.40
0.35
1.3
1.2
—
—
—
0
0
6
43
1.40
0.35
1.3
2.0
—
—
—
0
0
6
44
1.37
0.34
1.2
3.0
18.67
28.58
u/ml
—
6
44
81
747
1.12
0.34
3.7
4.1
5.28
8.58
mg/mmol
0.83
59
475
6
46
1.31
0.33
1.7
1.5
—
—
—
0
0
22
262
0.83
0.33
3.9
4.4
28.06
31.02
%
0.64
16
172
12
94
1.29
0.28
1.6
1.8
—
—
—
0
0
223
2179
1.12
0.28
5.1
4.2
1.37
1.28
mmol/l
0.99
212
2022
8
63
1.28
0.28
1.1
1.3
—
—
—
0
0
9
75
1.21
0.25
1.4
1.4
—
—
—
0
0
59
547
1.10
0.23
1.7
1.7
—
—
—
0
0
5
40
1.25
0.22
1.2
1.2
10.22
14.08
u/l
—
5
33
0
10
0.00
0.21
0.0
1.2
—
10.10
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
4.2
—
1.10
—
0
10
0
12
0.00
0.21
0.0
1.6
—
7.79
—
0
12
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
26
231
1.14
0.20
3.7
3.2
—
—
—
0
0
31
280
1.12
0.19
1.8
2.0
—
—
—
0
0
172
1680
1.06
0.16
5.2
3.7
56.44
47.40
u/l
0.54
165
1604
32
344
0.92
0.13
1.6
1.5
—
—
—
0
0
33
307
1.09
0.12
1.8
2.1
—
—
—
0
0
10
85
1.18
0.12
1.4
1.2
—
—
—
0
0
232
2298
1.06
0.10
5.9
5.0
4.71
4.66
mmol/l
0.28
221
2161
5
46
1.09
0.09
1.2
1.2
—
1.79
—
0
8
8
75
1.07
0.07
1.0
1.1
—
0.89
—
0
8
15
139
1.08
0.05
1.4
1.3
—
—
—
0
0
40
409
0.97
0.02
3.2
3.0
0.69
0.75
ug/l
0.15
24
249
228
2288
0.98
0.01
5.8
4.9
1.48
1.46
mmol/l
0.25
216
2135
16
154
1.04
0.00
1.4
2.3
—
—
—
0
0
13
133
0.98
0.00
1.3
2.3
—
—
—
0
0
233
2326
1.01
0.00
6.4
5.6
2.80
2.74
mmol/l
0.41
221
2170
0
7
0.00
0.00
0.0
2.6
—
44.74
—
0
7
0
7
0.00
0.00
0.0
1.0
—
0.16
—
0
7
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
5
53
0.94
-0.00
2.4
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
0.86
—
0
8
7
71
0.99
-0.00
1.1
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
16
160
1.00
-0.00
1.1
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
5
53
0.94
-0.00
1.4
1.5
1.12
0.81
nmol/l
—
5
47
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_MUSCOTHUNS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MUSCOTHUNS | 2.962 [2.19, 4.0] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.081 |
During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 719 females with G6_MUSCOTHUNS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MUSCOTHUNS | 2.651 [2.11, 3.34] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.024 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 773 males with G6_MUSCOTHUNS died.
Mortality risk
Mortality risk for people of age
years, who have G6_MUSCOTHUNS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.252% | 0.384% |
| 5 | 1.66% | 2.69% |
| 10 | 3.948% | 6.826% |
| 15 | 7.418% | 13.381% |
| 20 | 12.42% | 22.845% |
Relationships between endpoints
↥Index endpoint: G6_MUSCOTHUNS – Other and unspecified primary disorders of muscles
GWS hits: 12
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data